Press Releases April 20, 2026 04:05 PM

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026

Tactile Medical Announces Q1 FY2026 Earnings Release and Conference Call Scheduled for May 4, 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
TCMD

Tactile Medical (Nasdaq: TCMD), a leader in at-home therapies for chronic conditions, announced that it will release its fiscal year 2026 first quarter financial results on May 4, 2026, after market close. The company will host a conference call to discuss the results and answer investor questions.

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
TCMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Tactile Medical provides at-home therapy solutions for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.
  • The company will release Q1 fiscal 2026 financial results on May 4, 2026, followed by an investor conference call.
  • Tactile Medical focuses on improving patient quality of life and reducing healthcare costs through clinical collaboration and awareness efforts.

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2026 financial results will be released after the market closes on Monday, May 4, 2026.

Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 4, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13759535. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13759535. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries:
Sam Bentzinger
Gilmartin Group
[email protected]


Risks

  • The announcement is solely about the upcoming earnings release with no new operational or financial data, leading to uncertainty about the company's short-term performance.
  • Patient demand and reimbursement dynamics in the healthcare and medical devices sectors may impact future financial results.
  • Competition and regulatory changes in the medical technology sector introduce risk to sustained growth and access to care.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026